Popular Trials
Virus Therapy
Oncolytic Virus Therapy for Pancreatic Cancer
This trial is testing a virus that has been modified to attack cancer cells and also stimulate the immune system to help kill cancer cells. The virus will be injected into the tumor and the patient will also receive standard care treatment.
Virus Therapy
Cocaine Vaccine for Cocaine Addiction
This trial is testing a new anti-cocaine vaccine to see if it is safe and effective in people addicted to cocaine. The vaccine works by causing the body to create immunity to cocaine, which would then prevent the drug's effects on the brain.
Popular Filters
Trials for Cytomegalovirus Patients
Virus Therapy
Viral-Specific T-cell Therapy for Post-Transplant Viral Infections
This trial tests if donor T-cells can safely treat CMV & ADV infections post-transplant. The primary objective is to reduce viral load & secondary is to measure safety & long-term response.
Virus Therapy
Virus-Specific T-Cell Therapy for Infections
This trial tests special immune cells designed to fight specific viruses in patients with weak immune systems or those who have had transplants. These patients have infections that don't respond to regular treatments. The donor immune cells help attack the viruses in their bodies. This approach has shown promise in enhancing immune responses to viruses like CMV and EBV.
CAR T-cell Therapy
R-MVST Cells for Viral Infections
This trial is testing a cell therapy called R-MVST for safety and feasibility in patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. The cell therapy will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available.
Virus Therapy
Genetically Modified T-cells for Infections in Cancer Patients
This trial is testing the feasibility and safety of genetically modified T-cells to control viral infections in immunocompromised cancer patients. If successful, this could provide a new, less toxic option for treating these life-threatening infections.
Trials for CMV Patients
Virus Therapy
Viral-Specific T-cell Therapy for Post-Transplant Viral Infections
This trial tests if donor T-cells can safely treat CMV & ADV infections post-transplant. The primary objective is to reduce viral load & secondary is to measure safety & long-term response.
Virus Therapy
Virus-Specific T-Cell Therapy for Infections
This trial tests special immune cells designed to fight specific viruses in patients with weak immune systems or those who have had transplants. These patients have infections that don't respond to regular treatments. The donor immune cells help attack the viruses in their bodies. This approach has shown promise in enhancing immune responses to viruses like CMV and EBV.
CAR T-cell Therapy
R-MVST Cells for Viral Infections
This trial is testing a cell therapy called R-MVST for safety and feasibility in patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. The cell therapy will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available.
Virus Therapy
Genetically Modified T-cells for Infections in Cancer Patients
This trial is testing the feasibility and safety of genetically modified T-cells to control viral infections in immunocompromised cancer patients. If successful, this could provide a new, less toxic option for treating these life-threatening infections.
Trials With No Placebo
Virus Therapy
AdAPT-001 for Cancer
This trial is testing a new cancer treatment, AdAPT-001, which is an injected virus that kills cancer cells. The purpose is to find the highest dose that is safe and tolerable. If successful, this could be used to treat others with cancer in the future.
Virus Therapy
HLA-matched VSTs for Viral Infections Post Stem Cell Transplant
This trial is for patients who have had a stem cell transplant and have developed a viral infection that is not responding to standard therapy. In this trial, the patient will receive white blood cells that have been specially trained to fight the viral infection.
CAR T-cell Therapy
Adoptive Immunotherapy for Viral Infections
This trial is a Phase I-II dose-finding trial to determine the optimal dose of intravenous injection of donor-derived cytotoxic T lymphocytes specific for CMV, EBV, BKV, and Adenovirus.
T-cell Therapy
Donor T Cell Therapy for Adenovirus Infections
This trial is testing the side effects of a new treatment for patients with a weakened immune system and adenovirus-related disease. The treatment is made from donated blood cells and is designed to kill viruses that can cause infections.
Frequently Asked Questions
Introduction to adenovirus
What are the top hospitals conducting adenovirus research?
In the realm of clinical trials for adenovirus, several top hospitals are making significant strides in research and treatment. Nestled in Duarte, California, City of Hope is leading the charge with three active adenovirus trials and a total of three completed trials to date. Their first recorded trial took place in 2018, showcasing their commitment to exploring innovative approaches against this viral infection. In Washington D.C., Children's National Medical Center is also at the forefront with three ongoing adenovirus trials as well as a portfolio that includes six past studies since embarking on their first trial back in 2010.
Moving further north to Minneapolis, Minnesota, researchers at the University of Minnesota are actively engaged in three current adenovirus trials while having already conducted six previous investigations into this condition since launching their inaugural study in 2014. Meanwhile, Cleveland Clinic located in Ohio has two ongoing clinical tests dedicated to combating adenovirus alongside five accomplished studies that have been conducted over time after initiating its pioneering investigation on such cases starting from 2010.
Lastly but not least, Phoenix Children's Hospital situated amidst Arizona's capital city adds its name to this esteemed list with two active trials focused on combating adenovirus and contributing towards advancing our understanding through an additional three previously held investigations; theirs can be traced back only seven years ago when they commenced their maiden experiment revolving around this condition.
These prestigious medical institutions underscore efforts being made across locations and specialties to combat adenovirus infections effectively. The dedication displayed by these hospitals demonstrates a shared commitment towards finding better treatments and preventive measures against this viral menace which continues affecting individuals worldwide
Which are the best cities for adenovirus clinical trials?
Houston, Texas emerges as the leading city for adenovirus clinical trials with 12 ongoing studies. The trials in Houston focus on various treatments such as HLA-matched VSTs, Arm 1 Intratumoral LOAd703, and SAM-LNP-S. Saint Louis, Missouri follows closely behind with 9 active trials investigating Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, SAM-LNP-S, and Posoleucel (ALVR105). New york City also showcases promising research with 7 active trials exploring therapies like Posoleucel and Virus Specific T-cell (VST) infusion. Dallas, Texas and Los Angeles, California both have 6 active trials each that encompass a range of treatments including Posoleucel and Virus Specific T-cell (VST) infusion. These cities offer individuals seeking adenovirus clinical trial opportunities access to cutting-edge research options that may shape future treatment approaches.
Which are the top treatments for adenovirus being explored in clinical trials?
Adenovirus research is paving the way for potential new treatments, with two standout contenders being explored in clinical trials. First on the list is HLA-matched VSTs, currently undergoing investigation in one active trial exclusively focusing on adenovirus. This treatment approach made its debut in 2021 and shows promising potential. Another noteworthy contender is virus-specific T-cell (VST) infusion, also being tested in one active trial dedicated to tackling adenovirus infections. Initially listed back in 2018, this treatment avenue holds great promise for combating this viral menace. As researchers delve deeper into these innovative therapies, there's hope that effective solutions will emerge to combat adenovirus and improve patient outcomes worldwide.
What are the most recent clinical trials for adenovirus?
Recent clinical trials have brought forth promising advancements in the field of adenovirus treatment. One such trial, known as Cohort A, has entered Phase 2 and became available on September 1, 2023. Additionally, a Phase 1 study involving virus-specific cytotoxic T-lymphocytes for adenovirus was made accessible on January 6, 2023. Another Phase 1 trial focused on Ad5-yCD/mutTKSR39rep-ADP adenovirus and fSRS Arm for adenovirus commenced on November 29th,2022. Notably, the TILT-123 trial began its first phase of testing on May17th ,2022 while Posoleucel reached Phase III and became available from May11th ,2022 . These recent clinical trials are propelling us closer to effective treatments against adenovirus infections.
What adenovirus clinical trials were recently completed?
Recently completed clinical trials investigating adenovirus therapies have yielded promising results, highlighting the potential of this innovative treatment approach. These trials include a study sponsored by Novartis Pharmaceuticals Corporation that concluded in March 2021 and focused on evaluating an adenovirus-based therapy for respiratory diseases. Another notable trial was conducted by Johnson & Johnson and successfully completed in January 2021, exploring the use of an adenovirus vector vaccine against COVID-19. These advancements signify significant strides in harnessing the power of adenoviruses for therapeutic purposes and offer hope for future breakthroughs in treating various medical conditions.